Vicky McGrath, Interim CEO of Rare Diseases Ireland, stated in Health Committee that “Access to life-saving and curative therapies in this country is lagging behind that of our neighbours.” The slow paper-pushing and drug price haggling has a cost in human suffering.
HSE Delays Increase Human Suffering
Pictured in Health Committee (left to right): Philip Watt, Chair of the Rare Disease Task Force and CEO of Cystic Fibrosis Ireland; Vicky McGrath, Interim CEO, Rare Diseases Ireland; and Dr. Derek Mitchell, CEO The Irish Platform for Patient Organisations, Science & Industry
